retatrutide safety trial results VisualAbstract: reduces body weight by 17.5% in patients with obesity Triple hormone receptor agonist retatrutide

The Lancet , 397 (10278), 971984

2017: The FDA approves a long-acting, once weekly GLP-1 RA injectable exenatide (Bydureon BCise)

Ask whether a slower dose escalation or a lower maintenance dose might reduce sexual side effects while preserving weight loss benefits

And one firm safety line, because the internet keeps suggesting otherwise: none of this involves you splitting pens or drawing partial doses out of single-dose vials at your kitchen counter

Patients sensitive to side effects, those with early-stage diabetes, or individuals already making lifestyle changes may benefit most

With transparent pricing and both insurance and cash payment options, patients can access ongoing support without additional barriers